A new strain of Covid-19 is rapidly spreading throughout the United States. Known as Cicada, the BA.3.2 variant was originally discovered in Africa in November 2024 before its first case in the US surfaced in June 2025. Subsequently, it has been found in patients and the wastewater systems of 29 states nationwide.
Medical experts have indicated that the existing COVID-19 vaccine may not be as effective against this new strain due to its significant genetic differences from other variants. However, there is no evidence suggesting that Cicada is more perilous than recent strains.
Compared to prevalent SARS-CoV-2 strains, Cicada exhibits 70 to 75 genetic mutations in the virus segment responsible for cell entry, affecting vaccine efficacy. Viruses evolve through genetic mutations during replication within cells, with occasional mutations providing advantages for certain variants, facilitating their transmission.
The alterations in Cicada’s genetic makeup pose challenges for immune system recognition, potentially leading to wider infection spread. Despite its rapid transmission, Cicada does not appear to cause more severe illness than other circulating COVID-19 variants.
Common symptoms associated with Cicada are akin to typical Covid-19 signs, including cough, fever, sore throat, congestion, fatigue, loss of smell or taste, and gastrointestinal problems. These symptoms can vary and may subside with rest, hydration, and over-the-counter medications. Asymptomatic infections are also possible with Cicada, allowing individuals to spread the virus unknowingly.
The NHS identifies various potential Covid-19 symptoms for awareness.
